Tagged with clinical

China Writing in the special December 2022 edition of DIA’s Global Forum magazine – which focuses exclusively on decentralised clinical trials – on behalf of the DIA China Digital Health Community (DHC), Takeda’s Alicia He and Pfizer’s Mia Sun examine the progress made on decentralised and digitalised trials in China.  …

USA Clinical trial diversity not only allows for a better understanding of the safety and efficacy of new therapies in population subgroups but also plays a significant role in reducing health inequities. In conversation with PharmaBoardroom, outgoing president and global chief executive of the Drug Information Association (DIA) Barbara Lopez Kunz,…

USA Reflecting on a transformational decade at the helm of the Drug Information Association (DIA), Barbara Lopez Kunz highlights some of the key achievements and most significant trends that have emerged during her tenure. Lopez Kunz points to the DIA’s evolution into a truly global knowledge-sharing platform, the COVID-19 pandemic’s impact…

LatAm Yaneth Giha of FIFARMA – the leading association for the innovative pharmaceutical industry in Latin America – gives a bird’s-eye overview on some of the key trends in LatAm healthcare, from regulatory and access challenges to the impact of the COVID-19 pandemic, the region’s potential as a clinical trials hub,…

LatAm Florencia Davel, head of LatAm operations for Bristol Myers Squibb (BMS) looks back on a successful four years in position, shaping the regional organisation into a true biopharma player in line with a global strategy shift. Davel also casts her eye over the market access scenario in LatAm, why BMS…

Europe Writing in the DIA Global Forum’s special November 2022 issue on the Digital Virtuous Loop Karin Van Baelen and Susan Sandler – both of Janssen – and AbbVie’s Álmath Spooner look at Europe’s progress towards true real-world evidence integration and its potential impact on decision making across the healthcare continuum.…

USA A boom in decentralised clinical trials was an unexpected effect of the COVID-19 pandemic and subsequent lockdowns. However, these trials require expertise and technology that can differ significantly from those needed for clinical trials, as Curavit Clinical Research’s Joel Morse writes in the DIA Global Forum’s special November 2022 issue…

Egypt PhRMA’s Middle East & Africa (MEA) group appoints a ‘champion’ for each of its markets to bring the priorities of that country to the agenda of the MEA executive committee. Egypt’s champion is Amgen and – as the company’s MEA lead Mohammed Nasser describes – there is much to be…

Brazil After a successful international career, Andre Vivan da Silva recently returned to his native Brazil to become GSK’s country manager. He explains the importance of vaccination, in Brazil, and HIV in a country where GSK’s products treat at least half of its HIV patients. He also speaks about the company’s…

UK With the brief tenure of Liz Truss as Prime Minister already drawing to a close, the UK faces yet another new leader as the country attempts to extricate itself from the financial havoc wreaked by the Truss administration. Despite this backdrop, activity continues in the UK’s vibrant healthcare and life…

USA In the United States, clinical trials have long been criticized for inadequate inclusion of minority patients and consequently for not representing the country’s diverse population. The FDA recently released new guidance for improving diversity in clinical trials. According to its Drug Trials Snapshots Report for 2019, of the clinical trials…

USA Ramona Sequeira, recently appointed chair of the PhRMA board of directors and president of Takeda’s US Business Unit and Global Portfolio Commercialization, gives her take on how the biopharma industry can do more to address the systemic inequities in US healthcare, including community-focused grant programs, clinical trial diversity initiatives, and…